Company profile: Mirati Therapeutics
1.1 - Company Overview
Company description
- Provider of novel cancer therapeutics in clinical development and commercialization; product candidates include MGCD265, an oral, multi-targeted kinase inhibitor targeting the Met, VEGF, Ron and Tie-2 receptor tyrosine kinases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mirati Therapeutics
ImClone Systems
HQ: United States
Website
- Description: Provider of targeted biologic treatments and therapeutic antibodies for oncology, developing a portfolio to address the medical needs of patients with a variety of cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ImClone Systems company profile →
MOMA Therapeutics
HQ: United States
Website
- Description: Provider of precision-medicine drug discovery targeting molecular machines involved in disease, enabled by a biomechanics engine integrating biochemistry, biophysics, structural biology, computation, chemistry, and functional genomics. Advancing precision oncology programs toward clinical trials and collaborating with Roche on a five-year effort to identify critical cancer dependencies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MOMA Therapeutics company profile →
Morphic Therapeutics
HQ: United States
Website
- Description: Provider of oral integrin therapies in development to treat serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer; developing treatments for patients with immunological, fibrotic, neoplastic, and vascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphic Therapeutics company profile →
Pyxis Oncology
HQ: United States
Website
- Description: Provider of antibody therapeutics intended to promote the body's immune response to cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pyxis Oncology company profile →
CG Oncology
HQ: United States
Website
- Description: Provider of clinical-stage oncolytic immunotherapies targeting cancer, centered on the investigational agent cretostimogene grenadenorepvec for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Activities include Phase 3 trials BOND-003 (monotherapy in high-risk BCG-unresponsive NMIBC) and PIVOT-006 (intermediate-risk NMIBC), and the Phase 2 CORE-001 combination with pembrolizumab in high-risk BCG-unresponsive NMIBC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CG Oncology company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mirati Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mirati Therapeutics
2.2 - Growth funds investing in similar companies to Mirati Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mirati Therapeutics
4.2 - Public trading comparable groups for Mirati Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →